Table 1.
Patient baseline and follow-up characteristics (n=197)
| TDF/FTC +ZDV (n=71) | TDF/FTC +EFV (n=126) | p | |
|---|---|---|---|
| Baseline characteristics | |||
| Female, n (%) | 69 (97%) | 81 (64%) | <0.001 |
| Age (years), median (IQR) | 32 (29–37) | 39 (31–45) | 0.02 |
| WHO clinical stage, n (%) | 0.003 | ||
| Stage 1 | 59 (83%) | 81 (64%) | |
| Stage 2 | 12 (17%) | 35 (28%) | |
| Stage 3 | – | 10 (08%) | |
| Body mass index (kg/m2), median (IQR) | 24.0 (21.1–26.1) | 22.3 (20.2–25.2) | 0.04 |
| CD4 count (cells/mm3), median (IQR) | 388 (299–446) | 395 (323–498) | 0.09 |
| Plasma HIV-1 RNA (log10 copies/ml), median (IQR) | 4.6 (3.9–5.1) | 4.9 (4.3–5.4) | 0.007 |
| HIV subtype, n (%) | 0.10 | ||
| HIV 1 only | 66 (93%) | 124 (98%) | |
| HIV 1–2 dual | 5 (7%) | 2 (2%) | |
| Positive serum HBs antigen, n (%) | 9 (13%) | 15 (12%) | 0.87 |
| Haemoglobin (g/l), median (IQR) | 106 (98–113) | 108 (99–120) | 0.19 |
| Creatinine clearance<60 ml/min | 0 | 4 (3%) | 0.30 |
| Serum transaminases>1.25×ULN, n (%) | 1 (1%) | 5 (4%) | 0.42 |
| Cotrimoxazole started before inclusion, n (%) | 41 (58%) | 79 (63%) | 0.49 |
| Time on CTX (months), median (IQR) | 9.4 (2.2–27.5) | 7.3 (0.8–21.9) | 0.26 |
| Positive QuantiFERON®-TB Gold test, n (%) | 14 (20%) | 32 (28%) | 0.25 |
| Status at Month-6 | |||
| Dead | 0 | 2 (2%) | |
| Alive and in active follow-up | 67 (94%) | 121 (96%) | 0.28 |
| Lost to follow-up | 4 (6%) | 3 (2%) |
n: number; %: percentage; IQR: interquartile range; ULN: upper limit of normal; ml/min: millilitres per minute; g/l: grams per litre; kg/m2: kilograms per square metre; mm3: cubic millimetre: HBs antigen: hepatitis B surface antigen.
TDF: tenofovir; FTC: emtricitabine; ZDV: zidovudine; EFV: efavirenz.